STOCKHOLM, Sweden, Oct. 28, 2005 (PRIMEZONE) -- Active Biotech's President and CEO Sven Andreasson and CFO Hans Kolam will present and comment on the Interim report January-September 2005.
To listen and to view the presentation: please visit www.activebiotech.com.
To participate in the teleconference, please call +44 (0) 20 7162 0080 (U.K.).
To listen to the conference and/or to view the presentation afterwards, please call +44 (0) 20 7031 4064 (U.K.), access code 680233 or visit www.activebiotech.com.
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex(r) for RA. Active Biotech AB P.O. Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 20 50